还没做过化疗，EGFR是野生型的病友一定要去做ALK的检测

jzjqian 发表于 2012-7-25 15:45

) Y; ^+ D4 m' C1 i, n5 @                               
登录/注册后可看大图

5 N# b7 d0 P; P! d3 J0 C1 }5 B请教，像我这样的，手术22个月了，还能去原手术医院拿到病理作EGFR检查么？

* M; z7 n+ X0 H/ G可以，但要有针对性，

请问，肺鳞癌，只做过一次化疗，骨髓抑制严重，后吃特罗凯4个月基本无效，可以参加实验组吗？

不可以了,要没做过任何治疗的,包括化疗和靶向药

Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  


Sub-category:
1 j1 p2 Y: s+ M3 mMolecular Targets
7 \. F4 P9 O3 C: \0 n2 y1 Z/ C" p

; C$ v7 \- n0 C' YCategory:
Tumor Biology

4 d1 g5 P( R  j! u& r
) G& S0 ], s3 iMeeting:
+ ~$ C+ x$ `8 A. j, U5 H: r2011 ASCO Annual Meeting
2 f6 v- L) }: Q& o

Session Type and Session Title:
Poster Discussion Session, Tumor Biology
8 ?# F$ X9 l8 F1 d/ Y

" Q9 i9 E  g+ A, P+ d* P+ iAbstract No:
10517
* Y+ L) W3 U. Q7 h7 _8 K! p+ x5 s
3 ]1 B) {. `. P5 I( R6 T  |
Citation:
J Clin Oncol 29: 2011 (suppl; abstr 10517)
2 t+ @8 O8 V& h2 i' {: s( v3 G, X
7 W. |* `$ @/ Q
# v: `0 F1 P$ @* kAuthor(s):
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
) b# t* a6 }7 W$ H
& h. F! Y' i! Z8 B
* B# U2 |: I" w) Q8 ]
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.

Abstract Disclosures
2 a0 m: I8 F: L# \! u6 u5 Z& I0 ?
8 N/ h  _% ?0 {3 ]9 i; mAbstract:

: s+ V+ \, ^: u' T7 p  ]
# ^4 i; y* W9 l6 H3 I% q8 JBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.

* D; g  l$ g8 ?9 v  s* P
( e+ F3 _/ q7 a1 s) H- ^( `+ c$ C

由吴一龙教授牵头的A80810029临床试验上周启动，初诊未治疗的晚期肺腺癌患者检测到ALK阳性，可参加一线crizotinib 对比力比泰+卡铂的临床研究，药物全部免费，即使分配到力比泰组，疾病进展之后可免费获得crizotinib.

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

boeun 发表于 2012-11-18 16:37

8 k( t5 M1 g; A: n: U; C- L                               
登录/注册后可看大图

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

化疗过的没机会了

平安！ 发表于 2012-7-20 11:20

8 i6 L5 b8 F# m: u1 Q: m                               
登录/注册后可看大图

" U: u$ W( f0 A$ a, z, C+ x. ]: A1 q易瑞沙、特罗凯有效的病人基本上可以断定ALK（-）。极其罕见EGFR、ALK同时突变的。
ALK一个指标医院要900多 ...

6 p( e$ {7 y: C  W平安，真的没有希望吗？我弟弟虽然特罗凯有效，但是ＥＧＦＲ是野生型，不是突变啊。有没有必要去检测ＡＬＫ呢？

9 h: J& a& m- I: x1 i/ u现在病情进展，快没招儿了。

好像想加入挺困难的

小地方没条件做啊